J
John Q. Trojanowski
Researcher at University of Pennsylvania
Publications - 1538
Citations - 245534
John Q. Trojanowski is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Dementia & Alzheimer's disease. The author has an hindex of 226, co-authored 1467 publications receiving 213948 citations. Previous affiliations of John Q. Trojanowski include Vanderbilt University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Update on the neuropathological diagnosis of frontotemporal dementias.
TL;DR: The goal of the conference was to update previous FTD diagnostic criteria, taking into account recent research advances to refine guidelines for the clinical and neuropathological diagnosis of FTD.
Journal ArticleDOI
Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
TL;DR: The pre- Analytical, analytical and post-analytical sources of variability including sources inherent to kits, and procedures to decrease the variability are described are described.
Journal ArticleDOI
Quantification of modified amyloid β peptides in Alzheimer disease and down syndrome brains
Ritsuko Hosoda,Takaomi C. Saido,Laszlo Otvos,Takao Arai,David M. A. Mann,Virginia M.-Y. Lee,John Q. Trojanowski,Takeshi Iwatsubo +7 more
TL;DR: The abundance of the distinct forms of A β reported here in formic acid extracts of AD and DS frontal cortex suggests that these Aβ species could play important roles in the deposition of Aβ inAD and DS brains.
Journal ArticleDOI
Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease
TL;DR: Identification of analytes that are easily and reliably measured and can be used alone or in a multi-modal approach to provide an accurate prediction of underlying neuropathology for use in clinical trials of disease modifying treatments in FTLD is proposed.
Journal ArticleDOI
Glial differentiation predicts poor clinical outcome in primitive neuroectodermal brain tumors.
Anna J. Janss,Anthony T. Yachnis,Jeffrey H. Silber,John Q. Trojanowski,Virginia M.-Y. Lee,Leslie N. Sutton,Giorgio Perilongo,Lucy B. Rorke,Peter C. Phillips +8 more
TL;DR: Expression of GFAP in PNETs has prognostic power comparable with the most significant clinical factors currently used to predict clinical outcome, according to immunohistochemical evidence of other differentiation.